A2RL
23.4.2024 17:55:33 CEST | Business Wire | Press release
On Saturday, April 27th, Abu Dhabi will host a groundbreaking event, welcoming 10,000 spectators to witness the inaugural ASPIRE Abu Dhabi Autonomous Racing League (A2RL) at the iconic Yas Marina Circuit. This brand-new autonomous racing competition marks a significant milestone in motorsport history, billed as the largest league of its kind globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423980323/en/
Making History: ASPIRE to Launch Inaugural ‘Abu Dhabi Autonomous Racing League’ Redefining Future of Extreme Sport on April 27 (Photo: AETOSWire)
Eight teams will compete: Code19 Racing (one of the first independent autonomous racing entity from the USA), Constructor University (based in Germany and Switzerland), Fly Eagle (representing Beijing Institute of Technology from China and Khalifa University from the UAE), HUMDA Lab (a member of the Széchenyi István University Group from Hungary), KINETIZ (a collaboration between Singapore Nanyang Technological University and Kintsugi based in the UAE), PoliMOVE (representing Politecnico di Milano from Italy), UNIMORE (also from Italy - University of Modena and Reggio Emilia), and Technical University of Munich - TUM (from Germany), vying for a substantial prize purse of US$ 2.25 million.
The participating teams of coders and engineers will each have exclusive access to identical Dallara Super Formula SF23 cars, made possible through a partnership with Japan Race Promotions. These cars will be autonomized with autonomous racing stacks developed and integrated by the Technology Innovation Institute (TII). The sole variable lies in how each team utilizes their coding skills, AI algorithms, and machine learning software development expertise to teach their cars how to drive. Currently recognized as the fastest open-wheel race car in the world after Formula One, these cars can reach speeds of up to 300 km/h.
For the first time, the race format is poised to feature four autonomous cars driving on the racetrack simultaneously – a feat never before attempted. In a series of pre-qualifying races, the finale will showcase the top performers from the Lap Test and Speed Test, advancing to a final Overtaking Challenge to determine the ultimate winner. Additionally, an AI vs Human car race will unfold, with the Technology Innovation Institute (TII) embracing the electrifying challenge of pitting their autonomous car against former F1 driver – Daniil Kvyat. TII will aim to get as close as possible to the human lap time and will also demonstrate the autonomous car’s ability to drive without GPS assistance.
H.E. Faisal Al Bannai, Secretary General of the Advanced Technology Research Council - ASPIRE’s parent entity, and Advisor to the UAE President on Strategic Research and Advanced Technology Affairs, said: "In pushing the boundaries of technology under extreme conditions, we uncover new frontiers in science. This reimagined racing paradigm harnesses the pinnacle of coding skills, AI algorithms, and software development prowess — the very skill sets of the future. By leveraging these capabilities, we pave a path at the forefront of research and development, propelling Abu Dhabi to become a pivotal global hub for innovation."
ADNOC has come on board as title sponsor, providing crucial support, underscoring the widespread enthusiasm for advancing autonomous racing technology. H.E. Dr. Sultan Al Jaber, Minister of Industry and Advanced Technology, and Group MD & CEO of ADNOC, added: "As we navigate the path to UAE's industrial future, our commitment to in-country value and technological advancement stands unwavering. A2RL epitomizes our dedication to integrating cutting-edge technology including AI, driving competitiveness and economic growth across sectors. For decades, ADNOC has invested in the latest technology and innovation – from the control room, to the board room - to deliver the modern energy that powers our lives."
Organizer of A2RL, ASPIRE CEO Stephane Timpano said: "A2RL is more than just a race — it's a platform for testing and optimizing autonomous vehicle technologies, enhancing safety and reliability on public roads. With the support of local and international partners, we're bringing the mobility future - closer." The inaugural race has attracted a diverse array of sponsors, each contributing their expertise and resources to ensure the success of the development of the cutting-edge autonomized cars. Leading partners, such as Du, DMT, AWS, and Mubadala, have played pivotal roles in shaping the event’s trajectory, with media partners such Motorsports, Inc. Arabia, FastCompany Middle East, and What’s On, amplifying A2RL’s visibility.
Technical partners, including Dallara, Danisi Engineering, Meccanica 42, Kistler, Seyond, Eventagrate, Live in Five, Focal Point VR and Vislink, have lent their specialized knowledge to elevate the event's innovation and performance standards.
An exclusive Fan Zone promises an elevated experience for families, motorsport fans, and tech enthusiasts alike. With tailored activities, guests can immerse themselves in cutting-edge tech and gaming, including a captivating VR zone and the AI museum – Raceum. From 16:00 (GST) on April 27, young students from the A2RL STEM Competition will showcase their coding skills on 1:8 scale autonomous racing cars, with 18 schools competing to add excitement. The night concludes at 23:00 (GST), with activities including a podium ceremony for the winners, fireworks, a drone show, and an after-show concert with DJ Andre Soueid.
For those unable to attend in person, the excitement of Race Day will be accessible through various live streaming channels, including A2RL’s official YouTube and Twitch channels, motorsport.tv and the A2RL app. Interested parties are invited to visit the A2RL website and monitor social media channels for updates regarding the program schedule and details on viewing the race in their respective regions.
The inaugural A2RL event is part of Abu Dhabi Mobility Week, running from April 24 to May 1.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423980323/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom